Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Empagliflozin (25mg) + Sitagliptin (100mg) Tablet
Therapeutic Category
Antidiabetic, ENDOCRINOLOGY and Hormonal range, Endocrinology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Emplozin S 25 Tablet is a combination medication used in the management of Type 2 diabetes mellitus. This tablet contains two active ingredients: Empagliflozin and Sitagliptin, which work together to improve blood glucose control when combined with diet and exercise.
Empagliflozin belongs to the class of medications known as SGLT2 inhibitors. It works by reducing the reabsorption of glucose in the kidneys, allowing more glucose to be excreted through urine, thus helping lower blood sugar levels. Sitagliptin, a DPP-4 inhibitor, increases the levels of incretin hormones that regulate insulin and glucagon secretion in response to meals. This dual action results in improved control of both fasting and post-meal blood sugar levels.
Emplozin S 25 Tablet is prescribed for patients with Type 2 diabetes who require more than one medication to effectively control their blood sugar levels. It may be used in combination with other antidiabetic agents, depending on the individual needs of the patient.
The combination therapy provides a complementary approach to diabetes management, addressing both insulin resistance and increased glucose production. This makes it an effective treatment option for patients who struggle with blood glucose control despite other interventions.
Common side effects include gastrointestinal discomfort, headaches, and respiratory infections. Serious side effects may include low blood sugar, pancreatitis, or kidney problems.
Indicated for the treatment of Type 2 diabetes mellitus in adults to improve blood glucose control, as part of a comprehensive treatment plan that includes diet and exercise.
Should not be used in patients with a history of severe kidney disease or diabetic ketoacidosis. Regular monitoring of renal function is recommended during treatment.
Store in a cool, dry place at room temperature, away from direct sunlight. Keep out of the reach of children.
Composition : Empagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin (10mg) + Linagliptin (5mg)
Composition : Empagliflozin (25mg) + Linagliptin (5mg)
Composition : Empagliflozin (10mg) Tablet
Composition : Empagliflozin (12.5mg) + Metformin (1000mg)
Composition : Empagliflozin (12.5mg) + Metformin (500mg)
Composition : Empagliflozin (5mg) + Metformin (500mg)
Composition : Empagliflozin (10mg) + Sitagliptin 100mg
Composition : Empagliflozin (25mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This anti-diabetic combination is widely used in type 2 diabetes management, making it a strong prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic management. It is commonly prescribed by diabetologists and physicians for patients requiring dual therapy.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 25mg + Sitagliptin 100mg Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology and general medicine segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.